Myelin-associated glycoprotein (MAG, also known as Siglec-4) is a critical cell-surface adhesion molecule expressed by myelinating glial cells. By binding to neuronal receptors such as NgR1, NgR2, and gangliosides, MAG acts as a potent inhibitor of axonal regeneration following central nervous system (CNS) injury. Targeting the MAG pathway represents a major therapeutic avenue for spinal cord injury, stroke recovery, and neurodegenerative diseases.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAG drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MAG ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View MAG Products |
| Gene Delivery | MAG Promise-ORF / Lentivirus Full-length ORF for stable cell lines to perform neurite outgrowth assays. |
View MAG Products |
| Benchmark Ab | Anti-MAG Recombinant Antibody Recombinant positive control derived from clinical benchmark (GSK249320 sequence). |
View MAG Products |
| Validator | MAG siRNA Set For target knockdown and specificity verification in neuronal cultures. |
View MAG Products |
| Related Target A | RTN4R (NgR1) Primary neuronal receptor for MAG; essential for validating ligand-receptor blocking. |
View RTN4R Products |
| Related Target B | LINGO1 Co-receptor in the NgR1 complex; target for synergistic myelin-disinhibiting therapies. |
View LINGO1 Products |
| Related Target C | RGMA Repulsive Guidance Molecule A; co-expressed axonal inhibitor targeting overlapping regenerative pathways. |
View RGMA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species evaluation (Human/Rodent models) | Human, Mouse, and Rat MAG ortholog proteins available with >95% purity verified by SDS-PAGE. |
| Siglec subfamily off-target screening | Comprehensive Siglec family homolog panel (Siglec-3, -5, -7, -9, -15) strictly verified by mass spectrometry. |
| Lack of positive control references | Clinical Benchmark Antibodies (GSK249320 biosimilar) included for assay standardization. |
| False positives in cell-based screening | Sequence-verified siRNA sets included for target-specific knockdown controls. |
Live MAG R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of MAG is undergoing a clinical renaissance. While early monoclonal antibodies (such as GSK249320) paved the way in stroke recovery trials, the next wave of drug discovery is focused on multi-targeting strategies. Researchers are shifting from simple monospecific blocking antibodies to bispecific constructs and decoy receptor fusions that simultaneously neutralize MAG and other myelin-associated inhibitors like Nogo-A and OMgp.
Furthermore, local delivery systems and blood-brain barrier (BBB)-crossing technologies (such as receptor-mediated transcytosis shuttles) are being integrated into anti-MAG pipelines to maximize target engagement in the CNS while minimizing systemic exposure.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | GlaxoSmithKline, Academic Institutions | Stroke Recovery, Spinal Cord Injury | High-affinity binding assays (Need native glycosylated human MAG ECD-Fc) |
| Decoy Receptors / Fusion Proteins | Biotech Startups, Recombinant Pioneers | Multiple Sclerosis, Neurotrauma | Ligand competition & blocking assays (Need biotinylated NgR1/RTN4R proteins) |
| Gene Therapy / siRNA | Academic Medical Centers | Optic Neuropathy, Chronic SCI | In vitro knockdown validation (Need sequence-verified MAG siRNA sets) |